The repetitive telomeric DNA at chromosome ends is protected from unwanted repair by telomere-associated proteins, which form the shelterin complex in mammals. Recent works have provided new insights into the mechanisms of how human shelterin assembles and recruits telomerase to telomeres. Inhibition of telomerase activity and telomerase recruitment to chromosome ends is a promising target for anticancer therapy. Here, we summarize results of quantitative assessments and newly emerged structural information along with the status of the most promising approaches to telomerase inhibition in cancer cells. We focus on the mechanism of shelterin assembly and the mechanisms of how shelterin affects telomerase recruitment to telomeres, addressing the conceptual dilemma of how shelterin allows telomerase action and regulates other essential processes. We evaluate how the identified critical interactions of telomerase and shelterin might be elucidated in future research of new anticancer strategies.

LifeB Chromatin Molecular Complexes CEITEC and Functional Genomics and Proteomics National Centre for Biomolecular Research Faculty of Science Masaryk University CZ 62500 Brno Czech Republic

Zobrazit více v PubMed

Levy M.Z., Allsopp R.C., Futcher A.B., Greider C.W., Harley C.B. Telomere end-replication problem and cell aging. J. Mol. Biol. 1992;225:951–960. doi: 10.1016/0022-2836(92)90096-3. PubMed DOI

Erdel F., Kratz K., Willcox S., Griffith J.D., Greene E.C., de Lange T. Telomere recognition and assembly mechanism of mammalian shelterin. Cell Rep. 2017;18:41–53. doi: 10.1016/j.celrep.2016.12.005. PubMed DOI PMC

Janovič T., Stojaspal M., Veverka P., Horáková D., Hofr C. Human telomere repeat binding factor TRF1 replaces TRF2 bound to shelterin core hub TIN2 when TPP1 is absent. J. Mol. Biol. 2019 doi: 10.1016/j.jmb.2019.05.038. PubMed DOI

De Lange T. Shelterin-mediated telomere protection. Annu. Rev. Genet. 2018;52:223–247. doi: 10.1146/annurev-genet-032918-021921. PubMed DOI

Broccoli D., Smogorzewska A., Chong L., de Lange T. Human telomeres contain two distinct Myb-related proteins, TRF1 and TRF2. Nat. Genet. 1997;17:231–235. doi: 10.1038/ng1097-231. PubMed DOI

Janouskova E., Necasova I., Pavlouskova J., Zimmermann M., Hluchy M., Marini V., Novakova M., Hofr C. Human RAP1 modulates TRF2 attraction to telomeric DNA. Nucleic. Acids Res. 2015;43:2691–2700. doi: 10.1093/nar/gkv097. PubMed DOI PMC

Chen Y., Yang Y., van Overbeek M., Donigian J., Baciu P., de Lange T., Lei M. A shared docking motif in TRF1 and TRF2 used for differential recruitment of telomeric proteins. Science. 2008;319:1092–1096. doi: 10.1126/science.1151804. PubMed DOI

Ye J.Z.S., Donigian J.R., van Overbeek M., Loayza D., Luo Y., Krutchinsky A.N., Chait B.T., de Lange T. TIN2 binds TRF1 and TRF2 simultaneously and stabilizes the TRF2 complex on telomeres. J. Biol. Chem. 2004;279:47264–47271. doi: 10.1074/jbc.M409047200. PubMed DOI

Grill S., Tesmer V.M., Nandakumar J. The N terminus of the OB domain of telomere protein TPP1 is critical for telomerase action. Cell Rep. 2018;22:1132–1140. doi: 10.1016/j.celrep.2018.01.012. PubMed DOI PMC

Hu C., Rai R., Huang C., Broton C., Long J., Xu Y., Xue J., Lei M., Chang S., Chen Y. Structural and functional analyses of the mammalian TIN2-TPP1-TRF2 telomeric complex. Cell Res. 2017;27:1485–1502. doi: 10.1038/cr.2017.144. PubMed DOI PMC

Lei M., Podell E.R., Cech T.R. Structure of human POT1 bound to telomeric single-stranded DNA provides a model for chromosome end-protection. Nat. Struct. Mol. Biol. 2004;11:1223–1229. doi: 10.1038/nsmb867. PubMed DOI

Baumann P., Cech T.R. POT1, the putative telomere end-binding protein in fission yeast and humans. Science. 2001;292:1171–1175. doi: 10.1126/science.1060036. PubMed DOI

Loayza D., Parsons H., Donigian J., Hoke K., de Lange T. DNA binding features of human POT1—A nonamer 5′-TAGGGTTAG-3′ minimal binding site, sequence specificity, and internal binding to multimeric sites. J. Biol. Chem. 2004;279:13241–13248. doi: 10.1074/jbc.M312309200. PubMed DOI

Lim C.J., Zaug A.J., Kim H.J., Cech T.R. Reconstitution of human shelterin complexes reveals unexpected stoichiometry and dual pathways to enhance telomerase processivity. Nat. Commun. 2017;8:1075. doi: 10.1038/s41467-017-01313-w. PubMed DOI PMC

Revzin A. The Biology of Nonspecific DNA–Protein Interactions. CRC Press; Boca Raton, FL, USA: 1990.

Griffith J.D., Comeau L., Rosenfield S., Stansel R.M., Bianchi A., Moss H., de Lange T. Mammalian telomeres end in a large duplex loop. Cell. 1999;97:503–514. doi: 10.1016/S0092-8674(00)80760-6. PubMed DOI

Doksani Y., Wu J.Y., de Lange T., Zhuang X. Super-resolution fluorescence imaging of telomeres reveals TRF2-dependent t-loop formation. Cell. 2013;155:345–356. doi: 10.1016/j.cell.2013.09.048. PubMed DOI PMC

Nandakumar J., Cech T.R. Finding the end: Recruitment of telomerase to telomeres. Nat. Rev. Mol. Cell Biol. 2013;14:69–82. doi: 10.1038/nrm3505. PubMed DOI PMC

He Q., Zeng P., Tan J.-H., Ou T.-M., Gu L.-Q., Huang Z.-S., Li D. G-quadruplex-mediated regulation of telomere binding protein POT1 gene expression. BBA. 2014;1840:2222–2233. doi: 10.1016/j.bbagen.2014.03.001. PubMed DOI

De Lange T. Shelterin: The protein complex that shapes and safeguards human telomeres. Genes Dev. 2005;19:2100–2110. doi: 10.1101/gad.1346005. PubMed DOI

Chen J.L., Blasco M.A., Greider C.W. Secondary structure of vertebrate telomerase RNA. Cell. 2000;100:503–514. doi: 10.1016/S0092-8674(00)80687-X. PubMed DOI

Mitchell J.R., Collins K. Human telomerase activation requires two independent interactions between telomerase RNA and telomerase reverse transcriptase. Mol. Cell. 2000;6:361–371. doi: 10.1016/S1097-2765(00)00036-8. PubMed DOI

Chen J.-L., Opperman K.K., Greider C.W. A critical stem-loop structure in the CR4-CR5 domain of mammalian telomerase RNA. Nucleic. Acids Res. 2002;30:592–597. doi: 10.1093/nar/30.2.592. PubMed DOI PMC

Bley C.J., Qi X., Rand D.P., Borges C.R., Nelson R.W., Chen J.J.-L. RNA-protein binding interface in the telomerase ribonucleoprotein. PNAS. 2011;108:20333–20338. doi: 10.1073/pnas.1100270108. PubMed DOI PMC

Chen J.-L., Greider C.W. Determinants in mammalian telomerase RNA that mediate enzyme processivity and cross-species incompatibility. EMBO J. 2003;22:304–314. doi: 10.1093/emboj/cdg024. PubMed DOI PMC

Lai C.K., Miller M.C., Collins K. Roles for RNA in telomerase nucleotide and repeat addition processivity. Mol. Cell. 2003;11:1673–1683. doi: 10.1016/S1097-2765(03)00232-6. PubMed DOI PMC

Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L.C., Coviello G.M., Wright W.E., Weinrich S.L., Shay J.W. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011–2015. doi: 10.1126/science.7605428. PubMed DOI

Horn S., Figl A., Rachakonda P.S., Fischer C., Sucker A., Gast A., Kadel S., Moll I., Nagore E., Hemminki K., et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013;339:959–961. doi: 10.1126/science.1230062. PubMed DOI

Huang F.W., Hodis E., Xu M.J., Kryukov G.V., Chin L., Garraway L.A. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013;339:957–959. doi: 10.1126/science.1229259. PubMed DOI PMC

Dokal I. Dyskeratosis congenita. Hematol. Am. Soc. Hematol. Educ. Program. 2011;2011:480–486. doi: 10.1182/asheducation-2011.1.480. PubMed DOI

Lingner J., Hughes T.R., Shevchenko A., Mann M., Lundblad V., Cech T.R. Reverse transcriptase motifs in the catalytic subunit of telomerase. Science. 1997;276:561–567. doi: 10.1126/science.276.5312.561. PubMed DOI

Meyerson M., Counter C.M., Eaton E.N., Ellisen L.W., Steiner P., Caddle S.D., Ziaugra L., Beijersbergen R.L., Davidoff M.J., Liu Q., et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell. 1997;90:785–795. doi: 10.1016/S0092-8674(00)80538-3. PubMed DOI

Wu R.A., Tam J., Collins K. DNA-binding determinants and cellular thresholds for human telomerase repeat addition processivity. EMBO J. 2017;36:1908–1927. doi: 10.15252/embj.201796887. PubMed DOI PMC

Mitchell J.R., Wood E., Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature. 1999;402:551–555. doi: 10.1038/990141. PubMed DOI

Egan E.D., Collins K. Biogenesis of telomerase ribonucleoproteins. RNA. 2012;18:1747–1759. doi: 10.1261/rna.034629.112. PubMed DOI PMC

Nguyen T.H.D., Tam J., Wu R.A., Greber B.J., Toso D., Nogales E., Collins K. Cryo-em structure of substrate-bound human telomerase holoenzyme. Nature. 2018;557:190–195. doi: 10.1038/s41586-018-0062-x. PubMed DOI PMC

Alves D., Li H., Codrington R., Orte A., Ren X., Klenerman D., Balasubramanian S. Single-molecule analysis of human telomerase monomer. Nat. Chem. Biol. 2008;4:287. doi: 10.1038/nchembio.82. PubMed DOI

Jiang J., Miracco E.J., Hong K., Eckert B., Chan H., Cash D.D., Min B., Zhou Z.H., Collins K., Feigon J. The architecture of tetrahymena telomerase holoenzyme. Nature. 2013;496:187–192. doi: 10.1038/nature12062. PubMed DOI PMC

Egan E.D., Collins K. Specificity and stoichiometry of subunit interactions in the human telomerase holoenzyme assembled in vivo. Mol. Cell. Biol. 2010;30:2775–2786. doi: 10.1128/MCB.00151-10. PubMed DOI PMC

Wu R.A., Dagdas Y.S., Yilmaz S.T., Yildiz A., Collins K. Single-molecule imaging of telomerase reverse transcriptase in human telomerase holoenzyme and minimal RNP complexes. Elife. 2015;4 doi: 10.7554/eLife.08363. PubMed DOI PMC

Lue N.F. A physical and functional constituent of telomerase anchor site. J. Biol. Chem. 2005;280:26586–26591. doi: 10.1074/jbc.M503028200. PubMed DOI PMC

Moriarty T.J., Ward R.J., Taboski M.A.S., Autexier C. An anchor site-type defect in human telomerase that disrupts telomere length maintenance and cellular immortalization. Mol. Biol. Cell. 2005;16:3152–3161. doi: 10.1091/mbc.e05-02-0148. PubMed DOI PMC

Jurczyluk J., Nouwens A.S., Holien J.K., Adams T.E., Lovrecz G.O., Parker M.W., Cohen S.B., Bryan T.M. Direct involvement of the TEN domain at the active site of human telomerase. Nucleic Acids Res. 2011;39:1774–1788. doi: 10.1093/nar/gkq1083. PubMed DOI PMC

Armbruster B.N., Banik S.S., Guo C., Smith A.C., Counter C.M. N-terminal domains of the human telomerase catalytic subunit required for enzyme activity in vivo. Mol. Cell. Biol. 2001;21:7775–7786. doi: 10.1128/MCB.21.22.7775-7786.2001. PubMed DOI PMC

Schmidt J.C., Zaug A.J., Kufer R., Cech T.R. Dynamics of human telomerase recruitment depend on template-telomere base pairing. Mol. Biol. Cell. 2018;29:869–880. doi: 10.1091/mbc.E17-11-0637. PubMed DOI PMC

Podlevsky J.D., Chen J.J.-L. Evolutionary perspectives of telomerase RNA structure and function. RNA Biol. 2016;13:720–732. doi: 10.1080/15476286.2016.1205768. PubMed DOI PMC

Chan H., Wang Y., Feigon J. Progress in human and tetrahymena telomerase structure determination. Annu. Rev. Biophys. 2017;46:199–225. doi: 10.1146/annurev-biophys-062215-011140. PubMed DOI PMC

Theimer C.A., Blois C.A., Feigon J. Structure of the human telomerase RNA pseudoknot reveals conserved tertiary interactions essential for function. Mol. Cell. 2005;17:671–682. doi: 10.1016/j.molcel.2005.01.017. PubMed DOI

Shefer K., Brown Y., Gorkovoy V., Nussbaum T., Ulyanov N.B., Tzfati Y. A triple helix within a pseudoknot is a conserved and essential element of telomerase RNA. Mol. Cell. Biol. 2007;27:2130–2143. doi: 10.1128/MCB.01826-06. PubMed DOI PMC

Qiao F., Cech T.R. Triple-helix structure in telomerase RNA contributes to catalysis. Nat. Struct. Mol. Biol. 2008;15:634–640. doi: 10.1038/nsmb.1420. PubMed DOI PMC

Schmidt J.C., Zaug A.J., Cech T.R. Live cell imaging reveals the dynamics of telomerase recruitment to telomeres. Cell. 2016 doi: 10.1016/j.cell.2016.07.033. PubMed DOI PMC

Schmidt J.C., Dalby A.B., Cech T.R. Identification of human TERT elements necessary for telomerase recruitment to telomeres. Elife. 2014;3 doi: 10.7554/eLife.03563. PubMed DOI PMC

Zhao Y., Sfeir A.J., Zou Y., Buseman C.M., Chow T.T., Shay J.W., Wright W.E. Telomere extension occurs at most chromosome ends and is uncoupled from fill-in in human cancer cells. Cell. 2009;138:463–475. doi: 10.1016/j.cell.2009.05.026. PubMed DOI PMC

Cristofari G., Lingner J. Telomere length homeostasis requires that telomerase levels are limiting. EMBO J. 2006;25:565–574. doi: 10.1038/sj.emboj.7600952. PubMed DOI PMC

Xi L.H., Schmidt J.C., Zaug A.J., Ascarrunz D.R., Cech T.R. A novel two-step genome editing strategy with CRISPR-Cas9 provides new insights into telomerase action and TERT gene expression. Genome Biol. 2015;16 doi: 10.1186/s13059-015-0791-1. PubMed DOI PMC

Venteicher A.S., Abreu E.B., Meng Z., McCann K.E., Terns R.M., Veenstra T.D., Terns M.P., Artandi S.E. A human telomerase holoenzyme protein required for Cajal body localization and telomere synthesis. Science. 2009;323:644–648. doi: 10.1126/science.1165357. PubMed DOI PMC

Xin H., Liu D., Wan M., Safari A., Kim H., Sun W., O’Connor M.S., Songyang Z. TPP1 is a homologue of ciliate TEBP-β and interacts with POT1 to recruit telomerase. Nature. 2007;445:559. doi: 10.1038/nature05469. PubMed DOI

Zhong F.L., Batista L.F.Z., Freund A., Pech M.F., Venteicher A.S., Artandi S.E. TPP1 OB-fold domain controls telomere maintenance by recruiting telomerase to chromosome ends. Cell. 2012;150:481–494. doi: 10.1016/j.cell.2012.07.012. PubMed DOI PMC

Sexton A.N., Youmans D.T., Collins K. Specificity requirements for human telomere protein interaction with telomerase holoenzyme. J. Biol. Chem. 2012;287:34455–34464. doi: 10.1074/jbc.M112.394767. PubMed DOI PMC

Abreu E., Aritonovska E., Reichenbach P., Cristofari G., Culp B., Terns R.M., Lingner J., Terns M.P. TIN2-tethered TPP1 recruits human telomerase to telomeres in vivo. Mol. Cell. Biol. 2010;30:2971–2982. doi: 10.1128/MCB.00240-10. PubMed DOI PMC

Smogorzewska A., van Steensel B., Bianchi A., Oelmann S., Schaefer M.R., Schnapp G., de Lange T. Control of human telomere length by TRF1 and TRF2. Mol. Cell. Biol. 2000;20:1659–1668. doi: 10.1128/MCB.20.5.1659-1668.2000. PubMed DOI PMC

Marcand S., Gilson E., Shore D. A protein-counting mechanism for telomere length regulation in yeast. Science. 1997;275:986–990. doi: 10.1126/science.275.5302.986. PubMed DOI

O’Connor M.S., Safari A., Xin H.W., Liu D., Songyang Z. A critical role for TPP1 and TIN2 interaction in high-order telomeric complex assembly. Proc. Natl. Acad. Sci. USA. 2006;103:11874–11879. doi: 10.1073/pnas.0605303103. PubMed DOI PMC

Liu D., O’Connor M.S., Qin J., Songyang Z. Telosome, a mammalian telomere-associated complex formed by multiple telomeric proteins. J. Biol. Chem. 2004;279:51338–51342. doi: 10.1074/jbc.M409293200. PubMed DOI

Rice C., Shastrula P.K., Kossenkov A.V., Hills R., Baird D.M., Showe L.C., Doukov T., Janicki S., Skordalakes E. Structural and functional analysis of the human POT1-TPP1 telomeric complex. Nat. Commun. 2017;8:14928. doi: 10.1038/ncomms14928. PubMed DOI PMC

Wang F., Podell E.R., Zaug A.J., Yang Y.T., Baciu P., Cech T.R., Lei M. The POT1-TPP1 telomere complex is a telomerase processivity factor. Nature. 2007;445:506–510. doi: 10.1038/nature05454. PubMed DOI

Nandakumar J., Bell C.F., Weidenfeld I., Zaug A.J., Leinwand L.A., Cech T.R. The TEL patch of telomere protein TPP1 mediates telomerase recruitment and processivity. Nature. 2012;492:285–289. doi: 10.1038/nature11648. PubMed DOI PMC

Dalby A.B., Hofr C., Cech T.R. Contributions of the TEL-patch amino acid cluster on TPP1 to telomeric DNA synthesis by human telomerase. J. Mol. Biol. 2015;427:1291–1303. doi: 10.1016/j.jmb.2015.01.008. PubMed DOI PMC

Necasova I., Janouskova E., Klumpler T., Hofr C. Basic domain of telomere guardian TRF2 reduces d-loop unwinding whereas RAP1 restores it. Nucleic Acids Res. 2017;45:12170–12180. doi: 10.1093/nar/gkx812. PubMed DOI PMC

Berardinelli F., Coluzzi E., Sgura A., Antoccia A. Targeting telomerase and telomeres to enhance ionizing radiation effects in in vitro and in vivo cancer models. Mutat. Res. 2017;773:204–219. doi: 10.1016/j.mrrev.2017.02.004. PubMed DOI

Schrank Z., Khan N., Osude C., Singh S., Miller R.J., Merrick C., Mabel A., Kuckovic A., Puri N. Oligonucleotides targeting telomeres and telomerase in cancer. Molecules. 2018;23:2267. doi: 10.3390/molecules23092267. PubMed DOI PMC

Allsopp R.C., Vaziri H., Patterson C., Goldstein S., Younglai E.V., Futcher A.B., Greider C.W., Harley C.B. Telomere length predicts replicative capacity of human fibroblasts. PNAS. 1992;89:10114–10118. doi: 10.1073/pnas.89.21.10114. PubMed DOI PMC

Dikmen Z.G., Gellert G.C., Jackson S., Gryaznov S., Tressler R., Dogan P., Wright W.E., Shay J.W. In vivo inhibition of lung cancer by GRN163L: A novel human telomerase inhibitor. Cancer Res. 2005;65:7866–7873. doi: 10.1158/0008-5472.CAN-05-1215. PubMed DOI

Ruden M., Puri N. Novel anticancer therapeutics targeting telomerase. Cancer Treat. Rev. 2013;39:444–456. doi: 10.1016/j.ctrv.2012.06.007. PubMed DOI

Gryaznov S.M., Jackson S., Dikmen G., Harley C., Herbert B.-S., Wright W.E., Shay J.W. Oligonucleotide conjugate GRN163L targeting human telomerase as potential anticancer and antimetastatic agent. Nucleosides Nucleotides Nucleic Acids. 2007;26:1577–1579. doi: 10.1080/15257770701547271. PubMed DOI

Jackson S.R., Zhu C.-H., Paulson V., Watkins L., Dikmen Z.G., Gryaznov S.M., Wright W.E., Shay J.W. Antiadhesive effects of GRN163L-an oligonucleotide N3′->P5′ thio-phosphoramidate targeting telomerase. Cancer Res. 2007;67:1121–1129. doi: 10.1158/0008-5472.CAN-06-2306. PubMed DOI

Shea-Herbert B., Pongracz K., Shay J.W., Gryaznov S.M. Oligonucleotide N3′→P5′ phosphoramidates as efficient telomerase inhibitors. Oncogene. 2002;21:638. doi: 10.1038/sj.onc.1205064. PubMed DOI

Asai A., Oshima Y., Yamamoto Y., Uochi T.-A., Kusaka H., Akinaga S., Yamashita Y., Pongracz K., Pruzan R., Wunder E., et al. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res. 2003;63:3931–3939. PubMed

Gryaznov S., Pongracz K., Matray T., Schultz R., Pruzan R., Aimi J., Chin A., Harley C., Shea-Herbert B., Shay J., et al. Telomerase inhibitors—Oligonucleotide phosphoramidates as potential therapeutic agents. Nucleosides Nucleotides Nucleic Acids. 2001;20:401–410. doi: 10.1081/NCN-100002314. PubMed DOI

Jafri M.A., Ansari S.A., Alqahtani M.H., Shay J.W. Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. Genome Med. 2016;8:69. doi: 10.1186/s13073-016-0324-x. PubMed DOI PMC

Tokcaer-Keskin Z., Dikmen Z.G., Ayaloglu-Butun F., Gultekin S., Gryaznov S.M., Akcali K.C. The effect of telomerase template antagonist GRN163L on bone-marrow-derived rat mesenchymal stem cells is reversible and associated with altered expression of cyclin D1, CDK4 and CDK6. Stem Cell Rev. 2010;6:224–233. doi: 10.1007/s12015-010-9124-7. PubMed DOI

Salloum R., Hummel T.R., Kumar S.S., Dorris K., Li S., Lin T., Daryani V.M., Stewart C.F., Miles L., Poussaint T.Y., et al. A molecular biology and phase II study of Imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: A pediatric brain tumor consortium study. J. Neurooncol. 2016;129:443–451. doi: 10.1007/s11060-016-2189-7. PubMed DOI PMC

Chiappori A.A., Kolevska T., Spigel D.R., Hager S., Rarick M., Gadgeel S., Blais N., Von Pawel J., Hart L., Reck M., et al. A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer. Ann. Oncol. 2015;26:354–362. doi: 10.1093/annonc/mdu550. PubMed DOI PMC

Gomez-Millan J., Goldblatt E.M., Gryaznov S.M., Mendonca M.S., Herbert B.-S. Specific telomere dysfunction induced by GRN163L increases radiation sensitivity in breast cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 2007;67:897–905. doi: 10.1016/j.ijrobp.2006.09.038. PubMed DOI

Wu X., Zhang J., Yang S., Kuang Z., Tan G., Yang G., Wei Q., Guo Z. Telomerase antagonist Imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma. Oncotarget. 2017;8:13600–13619. doi: 10.18632/oncotarget.14618. PubMed DOI PMC

Ferrandon S., Malleval C., El Hamdani B., Battiston-Montagne P., Bolbos R., Langlois J.-B., Manas P., Gryaznov S.M., Alphonse G., Honnorat J., et al. Telomerase inhibition improves tumor response to radiotherapy in a murine orthotopic model of human glioblastoma. Mol. Cancer. 2015;14:134. doi: 10.1186/s12943-015-0376-3. PubMed DOI PMC

Puri N., Eller M.S., Byers H.R., Dykstra S., Kubera J., Gilchrest B.A. Telomere-based DNA damage responses: A new approach to melanoma. FASEB J. 2004;18:1373–1381. doi: 10.1096/fj.04-1774com. PubMed DOI

Ohashi N., Yaar M., Eller M.S., Truzzi F., Gilchrest B.A. Features that determine telomere homolog oligonucleotide-induced therapeutic DNA damage-like responses in cancer cells. J. Cell. Physiol. 2007;210:582–595. doi: 10.1002/jcp.20848. PubMed DOI

Pitman R.T., Wojdyla L., Puri N. Mechanism of DNA damage responses induced by exposure to an oligonucleotide homologous to the telomere overhang in melanoma. Oncotarget. 2013;4:761–771. doi: 10.18632/oncotarget.1047. PubMed DOI PMC

Puri N., Pitman R.T., Mulnix R.E., Erickson T., Iness A.N., Vitali C., Zhao Y., Salgia R. Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides. Cancer Lett. 2014;343:14–23. doi: 10.1016/j.canlet.2013.09.010. PubMed DOI PMC

Chhabra G., Wojdyla L., Frakes M., Schrank Z., Leviskas B., Ivancich M., Vinay P., Ganapathy R., Ramirez B.E., Puri N. Mechanism of action of G-quadruplex-forming oligonucleotide homologous to the telomere overhang in melanoma. J.Invest. Derm. 2018;138:903–910. doi: 10.1016/j.jid.2017.11.021. PubMed DOI

Longe H.O., Romesser P.B., Rankin A.M., Faller D.V., Eller M.S., Gilchrest B.A., Denis G.V. Telomere homolog oligonucleotides induce apoptosis in malignant but not in normal lymphoid cells: Mechanism and therapeutic potential. Int. J. Cancer. 2009;124:473–482. doi: 10.1002/ijc.23946. PubMed DOI PMC

Crees Z., Girard J., Rios Z., Botting G.M., Harrington K., Shearrow C., Wojdyla L., Stone A.L., Uppada S.B., Devito J.T., et al. Oligonucleotides and G-quadruplex stabilizers: Targeting telomeres and telomerase in cancer therapy. Curr. Pharm. Des. 2014;20:6422–6437. doi: 10.2174/1381612820666140630100702. PubMed DOI

Kolhatkar V., Khambati H., Lote A., Shanine P., Insley T., Sen S., Munirathinam G., Král P., Kolhatkar R. Star-shaped tetraspermine enhances cellular uptake and cytotoxicity of T-oligo in prostate cancer cells. Pharm. Res. 2015;32:196–210. doi: 10.1007/s11095-014-1455-7. PubMed DOI

Li G.-Z., Eller M.S., Hanna K., Gilchrest B.A. Signaling pathway requirements for induction of senescence by telomere homolog oligonucleotides. Exp. Cell. Res. 2004;301:189–200. doi: 10.1016/j.yexcr.2004.08.019. PubMed DOI

Van Steensel B., Smogorzewska A., de Lange T. TRF2 protects human telomeres from end-to-end fusions. Cell. 1998;92:401–413. doi: 10.1016/S0092-8674(00)80932-0. PubMed DOI

Ivancich M., Schrank Z., Wojdyla L., Leviskas B., Kuckovic A., Sanjali A., Puri N. Treating cancer by targeting telomeres and telomerase. Antioxidants. 2017;6:15. doi: 10.3390/antiox6010015. PubMed DOI PMC

Electron microscopy reveals toroidal shape of master neuronal cell differentiator REST - RE1-silencing transcription factor

Phosphorylation of TRF2 promotes its interaction with TIN2 and regulates DNA damage response at telomeres